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Background: Hemolytic uremic syndrome is a common cause of acute kidney injury in children. In children, hemolytic
uremic syndrome is most commonly associated with gasterointestinal infections caused by Shiga toxin-producing
Escherichia coli or other enteric organisms. Although less common, atypical hemolytic uremic syndrome is triggered by
multiple factors and portends a significantly worse prognosis with a high rate of recurrence.
Case presentation: Here we discuss the case of a 10 year old Caucasian male presenting with thrombocytopenia,
anemia, and acute kidney injury.
Conclusions: This case highlights the clinical challenges in diagnosing and managing patients with hemolytic uremic
syndrome. Because of similarity in symptoms, differentiating Shiga toxin-producing Escherichia coli associated hemolytic
uremic syndrome and atypical hemolytic uremic syndrome can be challenging. However, because of the increased
morbidity and mortality of atypical hemolytic uremic syndrome, early detection and initiation of therapy are critical.
Providers must have a heightened suspicion in order to initiate supportive care or disease directed therapy in the case
of atypical hemolytic uremic syndrome.
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Hemolytic uremic syndrome (HUS) is a systemic disease
manifested by acute kidney injury, thrombocytopenia,
and hemolytic anemia. In fact, HUS continues to be
cited as the most common cause of acute kidney injury
in young children [1]. Generally, HUS is associated with
gasterointestinal infections caused by Shiga toxin-
producing Escherichia coli (STEC) or other enteric or-
ganisms [1]. In the acute phase of the illness, two-thirds
of patients require renal replacement therapy with a ma-
jority of those patients experiencing renal recovery [1].
The mortality rate in STEC HUS is between 3-5% (1).
As only 10-15% of children infected with STEC progress
to HUS, it is hypothesized that an underlying genetic
predisposition or additional environmental stimuli may* Correspondence: Jack.Weaver@carolinashealthcare.org
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article, unless otherwise stated.be involved [1]. Non-STEC causes of HUS or atypical
HUS (aHUS) are typically associated with mutations in
regulatory proteins of the complement system in chil-
dren. More importantly, aHUS is associated with in-
creased morbidity and mortality. Current treatment
strategies for HUS generally focus on supportive care
including stabilization of the renal and hematologic
manifestations. Plasmapheresis, infusion of fresh frozen
plasma, and fibrinolytic therapy have been proposed to
have theoretical benefit, but based on a recent Cochrane
review, there is no evidence to support these interven-
tions at this time [2,3]. However, in aHUS, disease-
directed therapy is available but must be initiated quickly
to prevent significant sequelae.
Case presentation
A 10-year old male presented to an urgent care center
following 24 hours of non-bloody diarrhea and abdom-
inal pain. He was diagnosed with viral gastroenteritis
and oral rehydration was recommended. On day 5 ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Improvement in laboratory parameters upon initiation
of therapeutic plasma exchange. Daily therapeutic plasma
exchange was initiated on hospital day 4. The patient was then
transitioned to alternate day therapeutic plasma exchange. Plasma
exchange was discontinued on day 50.
Figure 2 Hematoxylin and eosin stain of glomeruli showing red
cell sludging and thrombi formation (arrow) typical of
hemolytic uremia syndrome.
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http://www.biomedcentral.com/1471-2431/14/278illness, his symptoms improved, but by day 8, he devel-
oped increasing listlessness and lethargy. By day 9 of
illness, the patient developed non-bloody, non-bilious
emesis and was re-evaluated at the urgent care center.
He was again diagnosed with viral gastroenteritis al-
though laboratory studies were obtained prior to dis-
charge. The parents were notified on day 12 of illness
that these studies were significantly abnormal. The
patient was brought to the local emergency room and
admitted to the Pediatric ICU for further management.
Upon arrival, the patient was lethargic and confused.
His vital signs demonstrated tachycardia and hyperten-
sion. His pupils were round, equal and reactive to light
bilaterally. He had bloody crusting at nares bilaterally.
His respiratory, cardiac, abdominal, and musculoskeletal
exams were normal. His skin exam demonstrated jaun-
dice and bruising on his legs. Despite difficulty focusing
and communicating, he did have purposeful movements
with painful stimuli and bilateral ankle clonus. Labora-
tory studies confirmed a hemoglobin of 4.5 g/dl and a
platelet count of 86 K/ul. His basic metabolic panel re-
vealed a sodium of 124 mg/dl, a potassium of 6.0 mg/dl,
a bicarbonate of 13 mg/dl, a blood urea nitrogen of
329 mg/dl, and a creatinine of 21.8 mg/dl (Figure 1).
Additional labs included a LDH of 4067 IU/L and a PTT
of 27 seconds. A chest radiograph was obtained and was
remarkable for pulmonary edema.
Following platelet and packed red blood cell tranfu-
sions because of the potential for bleeding, a temporary
external jugular hemodialysis catheter was placed and
hemodialysis was initiated. A renal ultrasound was nor-
mal. A percutaneous renal biopsy was performed on
hospital day 3 to confirm the diagnosis and to examine
the degree of chronicity because of the severity of acute
kidney injury. Results from the biopsy demonstrated the
presence of a thrombotic microangiopathy on hospital
day 4 (Figures 2 and 3). Because of the severity of his ill-
ness and concern for atypical causes of HUS, therapeutic
plasma exchange (TPE) was initiated on hospital day
four. Laboratory studies at that time revealed a normal
complement C3 level, a normal complement C4 level,
and a negative anti-neutrophil antibody titer. ADAMTS
13 activity was also normal at 40%. Once stool was avail-
able on hospital day 6, a sample was obtained for bac-
terial culture and to assess for Shiga-like toxin using
enzyme-linked immunoabsorbent assay simultaneously.
After 48 hours, stool culture demonstrated no bacterial
growth including no evidence of Escherchia coli O157:
H7 on Sorbitol-MacConkey. Genetic studies for muta-
tions in complement system regulatory proteins were
also obtained. He was extubated on day 6. The patient
was maintained on daily TPE for five sessions and tran-
sitioned to alternate day TPE on hospital day 9 with
stabilization of his renal function and hematologic
Figure 3 Jones stain showing fibrin thrombi and vascular
congestion of glomeruli suggestive on hemolytic
uremia syndrome.
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hospital day 10 (Figure 1). The patient was discharged
on hospital day 12 and continued to receive alternate
day TPE as an outpatient (Figure 1). Laboratory studies
at discharge included a BUN of 26 mg/dl, serum creatin-
ine of 1.71 mg/dl, hemoglobin on 7.1 g/dl, platelets of
170 k/L, and a LDH of 262 IU/L. Following discharge, a
stool sample was positive for E. coli Shiga like toxin
based on enzyme immunoassay. Based on this result, the
frequency of TPE was decreased and ultimately discon-
tinued on day 50 following his diagnosis. His laboratory
studies remained normal upon discontinuation of TPE.
However, results from genetic testing obtained while
hospitalized returned 3 months following his illness
revealed mutations in regulatory components of the al-
ternative complement pathway including a heterozygous
missense mutation in complement Factor H (Gln950His)
as well as a homozygous deletion in complement factor
H-related genes, CFHR1 and CFHR3. Autoantibody to
Factor H was negative.
Despite discontinuation of therapy and his initial renal
dysfunction, the patient continued to maintain normal
electrolytes, normal hematologic studies, normal renal
function, normal blood pressure, and a normal urinaly-
sis. Therefore, TPE was not restarted. A year following
his initial diagnosis he has not had any recurrence of his
disease, and laboratory studies are remarkable for a
serum creatinine of 0.47 mg/dl, platelets of 381 K/uL,
and LDH of 182 IU/L.
Conclusions
In the case discussed above, the patient demonstrated
a prodromal illness of loose stools and emesis with
subsequent development of thrombocytopenia, anemia,
and acute kidney injury consistent with STEC HUS.However, because of the severity of his renal dysfunction
and lack of definitive evidence for STEC on stool cul-
ture, TPE was initiated. Anecdotally, TPE has purported
benefits in patients with STEC HUS although a recent
meta-analysis argued against these conclusions [2]. An-
other consideration for initiation of TPE was the possi-
bility of aHUS which is associated with alterations in
regulatory factors of the complement system [4]. These
mutations lead to unregulated activation of the alterna-
tive complement pathway, activation of the membrane
attack complex, and endothelial damage [4]. Although
less frequent, aHUS has a poor prognosis with 50% of
cases progressing to end stage renal disease (ESRD) and
a mortality rate of 25% during the initial episode [4]. In
addition, aHUS has a high risk of recurrence [4]. As
patients with aHUS can often have non-specific gaster-
ointestinal complaints, the distinction between the pre-
sentations of patients with STEC HUS compared to
patients with aHUS is often difficult [4]. Unfortunately,
definitive genetic testing is only performed at a few
laboratories in North America and often takes 3-4
months. Most importantly, treatment strategies to pre-
vent this morbidity and mortality are available including
plasma exchange, plasma infusion, as well as a human-
ized monoclonal antibody (Eculizumab) that blocks
activation of the terminal complement pathway [3].
Therefore, providers must maintain a high index of sus-
picion and initiate therapy often in the absence of con-
firmatory testing [4]. As illustrated above, the patient
demonstrated a rapid improvement in both hematologic
and renal parameters upon initiation of TPE. But 9 days
into treatment, confirmatory testing for Shiga-toxin was
positive on enzyme immunoassay (EIA) suggesting that
STEC triggered the development of HUS [5]. Recent
guidelines suggest that simultaneous culture for O157
STEC and EIA testing for Shiga toxin is more effective
at detecting STEC than each method alone for several
reasons including bacteria are difficult to detect after
1 week of illness and non O157 STEC may be causing
disease [5]. As a result, the patient’s plasma exchange
therapy was gradually weaned, and his hematologic pa-
rameters as well as his renal function remained normal.
Unexpectedly, genetic studies obtained at the time of
presentation and resulted three months later indicated
that the patient possessed mutations in complement
regulatory factors that are associated with development
of aHUS specifically complement factor H (CFH) and as
well as a homozygous deletion in complement factor H-
related genes [6,7]. CFH is a critical regulator of the
alternative complement cascade preventing generation
of terminal complement components and the membrane
attack complex [6]. Mutations in CFH are the most
commonly identified genetic abnormality in patients
with aHUS. In fact, the mutation noted in the current
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aHUS in the literature and is thought to alter the C-
terminal domain of CFH [8]. Mutations in CFHR1/
CFHR3 are found in 32% of patients with aHUS and as-
sociated with development of CFH antibodies which is a
risk factor for the development of aHUS [7]. The current
patient did not demonstrate CFH autoantibodies. In the
absence of CFH autoantibodies, the significance of dele-
tions of CFHR1/CFHR3 with a simultaneous mutation
in CFH has not been described. Interestingly, incomplete
penetrance is reported for all of the genes associated
with aHUS [8]. Even in patients with mutations in two
genes associated with aHUS, penetrance is still incom-
plete. These data suggest that development of the clin-
ical findings of aHUS is dependant on other genetic risk
factors and environmental events [9]. Specifically, 70% of
cases of aHUS with mutations in CFH are preceded by
an infection [6]. Pregnancy and medications are associ-
ated with precipitation of the clinical manifestations of
aHUS in 8% of cases [6]. Therefore, in concert with
mutations in complement regulatory factors and other
genetic risks, an environmental trigger is required to
initiate the unregulated activation of the complement
system and development of HUS [10]. In the patient
described above, the environmental trigger was hypo-
thesized to be Shiga toxin-mediated damage of the
endothelial cell. The presence of these genetic risk fac-
tors may have also influenced the severity of his renal
presentation.
The clinical implications of these results suggested
that as opposed to a majority of patients with STEC-
associated HUS, the patient described above is at risk for
recurrence of his disease [1,4]. A recent article describ-
ing a cohort of patients with aHUS found that the risk
of recurrence is approximately 40% which decreases to
25% after the first year [11]. Therefore, close monitoring
of laboratory studies remains critical in these patients
particularly during times of acute illness. Furthermore,
with the development of novel therapies that seem to
block complement-mediated damage associated with
aHUS, the clinical dilemma becomes when to initiate di-
rected therapy for HUS as early intervention significantly
improves clinical outcomes [11,12]. At present, the pa-
tient described above does not demonstrate any signs of
recurrent disease. Despite his initial serum creatinine of
21 mg/dl, he maintains normal renal function, normal
hematologic parameters, normal blood pressures, and
normal urinalysis. Therefore, there is no indication for
disease-specific therapy at this time. However, the
patient’s family has been counseled extensively on the
importance of obtaining laboratory studies at signs of
fever, illness, or other factors associated with a recur-
rence of HUS so that therapy could be initiated as early
as possible.In summary, this case highlights the clinical challenges
in managing patients with HUS. Despite recent advances
in the pathophysiology of STEC HUS, several issues
remain including identifying the genetic and environ-
mental factors that confer susceptibility for development
of HUS in select patients following infection with STEC.
In addition, because the symptoms of STEC associated
HUS overlap with symptoms noted in patients with
aHUS, providers must have a heightened suspicion in
order to initiate supportive care or disease directed ther-
apy in the case of aHUS. Finally, additional research is
required to determine if a subset of patients with STEC
HUS such as the patient described above may benefit
from solely supportive care or disease specific therapy.
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